ZA201906127B - Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use - Google Patents

Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Info

Publication number
ZA201906127B
ZA201906127B ZA2019/06127A ZA201906127A ZA201906127B ZA 201906127 B ZA201906127 B ZA 201906127B ZA 2019/06127 A ZA2019/06127 A ZA 2019/06127A ZA 201906127 A ZA201906127 A ZA 201906127A ZA 201906127 B ZA201906127 B ZA 201906127B
Authority
ZA
South Africa
Prior art keywords
dimethoxyquinolin
dicarboxamide
cyclopropane
fluorophenyl
oxy
Prior art date
Application number
ZA2019/06127A
Other languages
English (en)
Inventor
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201906127(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ZA201906127B publication Critical patent/ZA201906127B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
ZA2019/06127A 2017-05-26 2019-09-17 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use ZA201906127B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
ZA201906127B true ZA201906127B (en) 2022-11-30

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/06127A ZA201906127B (en) 2017-05-26 2019-09-17 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Country Status (20)

Country Link
US (3) US11279675B2 (enExample)
EP (1) EP3630726B1 (enExample)
JP (3) JP7166292B2 (enExample)
KR (1) KR102611445B1 (enExample)
CN (1) CN110621662B (enExample)
AU (1) AU2018272088C1 (enExample)
CA (1) CA3060370A1 (enExample)
DK (1) DK3630726T3 (enExample)
EA (1) EA039654B1 (enExample)
ES (1) ES2909390T3 (enExample)
HU (1) HUE058196T2 (enExample)
IL (1) IL270780B2 (enExample)
MA (1) MA48776A (enExample)
MX (1) MX2019012505A (enExample)
PL (1) PL3630726T3 (enExample)
PT (1) PT3630726T (enExample)
SG (1) SG11201909161PA (enExample)
UA (1) UA127760C2 (enExample)
WO (1) WO2018218233A1 (enExample)
ZA (1) ZA201906127B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015218236B2 (en) * 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
IL270780B2 (en) * 2017-05-26 2025-04-01 Exelixis Inc Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
EP4631505A3 (en) * 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
SG11202111978VA (en) * 2019-06-03 2021-11-29 Exelixis Inc Crystalline salt forms of a kinase inhibitor
WO2023165948A1 (en) 2022-03-01 2023-09-07 Synthon B.V. Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
DK2621481T4 (da) 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
TWI640509B (zh) 2011-02-10 2018-11-11 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
TWI610918B (zh) 2011-05-02 2018-01-11 艾克塞里克斯公司 治療癌症及骨癌疼痛之方法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
WO2013066296A1 (en) 2011-10-31 2013-05-10 Hewlett-Packard Development Company, L.P. Method of fabricating a color filter array using a multilevel structure
EP2776033A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
EP2775921A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Method of quantifying cancer treatment
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
AU2015218236B2 (en) * 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2015177758A1 (en) * 2014-05-23 2015-11-26 Mylan Laboratories Ltd Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
WO2016150966A1 (en) 2015-03-25 2016-09-29 Sandoz Ag Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US10980792B2 (en) * 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
IL270780B2 (en) * 2017-05-26 2025-04-01 Exelixis Inc Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use

Also Published As

Publication number Publication date
MA48776A (fr) 2020-04-08
KR20200010205A (ko) 2020-01-30
JP7166292B2 (ja) 2022-11-07
US20220162166A1 (en) 2022-05-26
CN110621662A (zh) 2019-12-27
CA3060370A1 (en) 2018-11-29
AU2018272088C1 (en) 2022-09-22
DK3630726T3 (da) 2022-03-07
EA039654B1 (ru) 2022-02-22
EP3630726A1 (en) 2020-04-08
US11279675B2 (en) 2022-03-22
EA201992803A1 (ru) 2020-04-16
JP2022145852A (ja) 2022-10-04
US11731941B2 (en) 2023-08-22
IL270780B1 (en) 2024-12-01
US20210261509A1 (en) 2021-08-26
JP2020521732A (ja) 2020-07-27
EP3630726B1 (en) 2021-12-22
IL270780B2 (en) 2025-04-01
WO2018218233A1 (en) 2018-11-29
UA127760C2 (uk) 2023-12-27
CN110621662B (zh) 2023-06-23
AU2018272088B2 (en) 2022-06-16
SG11201909161PA (en) 2019-10-30
AU2018272088A8 (en) 2019-10-24
IL270780A (en) 2020-01-30
NZ757564A (en) 2025-05-02
HUE058196T2 (hu) 2022-07-28
JP7437460B2 (ja) 2024-02-22
JP2024036690A (ja) 2024-03-15
JP7659097B2 (ja) 2025-04-08
ES2909390T3 (es) 2022-05-06
US20240010621A1 (en) 2024-01-11
MX2019012505A (es) 2019-12-19
PT3630726T (pt) 2022-03-02
PL3630726T3 (pl) 2022-05-09
AU2018272088A1 (en) 2019-10-17
US12227481B2 (en) 2025-02-18
KR102611445B1 (ko) 2023-12-06

Similar Documents

Publication Publication Date Title
ZA201605424B (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
IL270780A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MA49696A (fr) Sel d'un composé dérivé d'aminopyridine, forme cristalline de celui-ci, et son procédé de préparation
EP3453703A4 (en) CRYSTALLINE FORM OF TAFAMIDIS-METHYLGLUCAMINE SALT AND MANUFACTURING METHOD AND APPLICATION THEREOF
IL282006A (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
PL3207928T3 (pl) Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych
EP3551612A4 (en) PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
IL263004B (en) A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
HUE056419T2 (hu) Vilanterol trifenatát amorf formája, és eljárások ennek elkészítésére
ZA202200964B (en) Salts of a compound, crystal forms of the salts and preparation method and use thereof
IL290625A (en) Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use
WO2019240698A3 (en) Oral pharmaceutical composition comprising posaconazole
SG11202111558VA (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
EP3901157A4 (en) NEW COMPOUND AND HAIR GROWTH STIMULATOR COMPOSITION INCLUDED THIS
EP3889157C0 (en) SALT AND CRYSTALLINE FORM OF A FUROPYRIMIDINE COMPOUND AND THEIR PHARMACEUTICAL USE
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof
PL3898612T3 (pl) Podstawione pirydynyloksybenzeny, ich sole oraz zastosowanie jako aktywne składniki herbicydowe
HK40075950A (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
HK40004900A (en) Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate